OmniAb®

OmniAb, Inc.

Nasdaq: OABI



Credit Suisse - 31st Annual Healthcare Conference

Rancho Palos Verdes, CA

November 7-10, 2022

Disclaimer

We caution you that this presentation contains forward-looking statements.

All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected cash runway, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, our technology platform and other technologies, our expectations regarding the addressable markets for our technologies, including the growth rate of the markets in which we operate, the timing of the initiation or completion of preclinical studies and clinical trials by our partners, expectations regarding product approvals and potential for future revenue growth, launches by our partners and the timing thereof, and the potential for and timing of receipt of milestones and royalties under our license agreements with partners, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: the anticipated benefits of our separation from Ligand may not be achieved; our future success is dependent on acceptance of our technology platform by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain, risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; regulatory developments in the United States and foreign countries; unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price; we may use our capital resources sooner than we expect; and other risks described in our press releases and filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made, and except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Information regarding partnered products and programs comes from information publicly released by our partners.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about the antibody industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

OmniAb, Inc.

OUR BUSINESS MODEL IS FOCUSED ON LICENSING OUR PROPRIETARY DISCOVERY TECHNOLOGY

ONE OF THE LARGEST GREENFIELDS IN THE PHARMA INDUSTRY

$236 BILLION TOTAL ADDRESSABLE MARKET FOR ANTIBODIES BY 2025

LEADING AND PROVEN TECHNOLOGY

GROWING ROSTER OF PARTNERS
GROWING NUMBER OF PROGRAMS
RECENT PRODUCT APPROVALS

GLOBALLY-RECOGNIZED SCIENCE AND TEAM

HISTORY OF FIRSTS IN GENETIC ENGINEERING
EXPANDING TECHNOLOGY AND CAPABILITIES

WE ARE MEETING A GLOBAL INDUSTRY NEED,

POISED FOR GROWTH

OmniAb®

Mission

Our mission is to enable the rapid development of innovative therapeutics by **pushing the frontiers of drug discovery technologies**.

OmniAb

The OmniAb Platform

LICENSES TO OUR TECHNOLOGY PLATFORM ARE STRUCTURED TO ALIGN ECONOMIC AND SCIENTIFIC INTERESTS WITH OUR PARTNERS



Technology offering addresses critical industry needs and is paired with our highly specialized and efficient operations

We leverage our proprietary and differentiated technologies, rather than commoditized industry services that are widely available from CROs or built into big pharma

Antibodies and Industry Demand

HIGHER SUCCESS RATES FOR ANTIBODY MEDICINES DRIVE OUR INDUSTRY'S NEED FOR DISCOVERY TECHNOLOGY

Increasing Antibody Market

- **$236B in antibody sales by 2025** (up from ~$212B in 2021)
- **49 blockbuster antibodies in 2021** (up from 41 in 2020)
- 5 best-selling antibodies had **~$66B of sales in 2021**

Higher Success Rates

Type of Drug	Clinical Success Rates(1)
Small Molecules	7.5%
Antibodies	**12.1%**

Historical success rates for antibodies are **significantly higher** than small molecules

Acceleration of Regulatory Approvals (FDA and EMA)



Sources:
2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics (La Merie Publishing).
Tables of approved mAbs and antibodies in review available at https://www.antibodysociety.org/resources/approved-antibodies/
(1) Defined as composite success rate of clinical development from Phase I trials to Approval, data from 2011-2020. Source: BIO | QLS Advisors | Informa Feb 2021 Report.

OmniAb

The OmniAb Platform

	Create Diverse Antibody Pools	Screen Antibody Candidates	Identify the Right Antibody
	Create Diverse Pools of High-Quality Naturally-Optimized Antibodies	*Screen Millions of Cells to Find Potential Therapeutic Candidates*	*Further Characterize, Select & Optimize the Right Antibody*
Technologies	 *Computational Antigen Design & Proprietary Reagents*	 *xPloration High-Throughput Single Cell Screening*	• *Custom Bioinformatics* • *Next Generation Sequencing (NGS) Hit Expansion* 
	OmniRat® OmniChicken® OmniMouse® *Robust Antibodies for Any Target*	 *Gel Encapsulated Microenvironment (GEM) Single Cell Screening*	 • *Comprehensive Functional Characterization* • *Proprietary Ion Channel Assays*
	OmniFlic® OmniClic® *Bispecific Antibody Generation*	OmniTaur™ *Cow-inspired Antibodies for Difficult Targets*	

Technology offering addresses the most critical challenges of antibody discovery

OmniAb®

What is *Biological Intelligence*™?

- We believe that antibodies generated *in vivo* are superior to ones from other sources because they are **naturally optimized** through an iterative process that preferentially selects for antibodies with excellent specificity and developability profiles
- The ability of the immune system in our engineered transgenic animals to create optimized antibodies for human therapeutics is what we call ***Biological Intelligence***
- We believe this approach **increases the efficiency and probability of success** of therapeutic antibody discovery and may help limit the attrition of antibody product candidates in the clinic

The OmniAb Platform

Antibody Generation Technologies



Computational Antigen Design & Proprietary Reagents

OmniRat OmniMouse OmniChicken

Antibodies for Any Target

OmniFlic OmniClic

Bispecific Antibody Generation

OmniTaur

Cow-inspired Antibodies for Difficult Targets

We believe generating **large and diverse** pools of high-quality antibodies increases the likelihood of **discovering the antibody** with the **most desirable therapeutic characteristics**

- *Industry's only 4-species platform*
- *3 approved and 22 active clinical-stage antibodies*
- *A rich heritage of genetic engineering advancements*
- *Carefully designed transgenes for robust response*
- *Bispecific and cow-inspired technologies enable next-generation therapeutics*

Rodent Platforms

OmniRat

OmniMouse

- Endogenous Ig genes inactivated
- Expression of full human V gene diversity
- Streamlined conversion into fully human molecule



Well-validated transgene design utilizes rodent constant regions for robust immune responses from the B-cell repertoire

Geurts et al. Science 2009
Ménoret et al. Eur J Immunol 2010
Osborn et al. J. Immunol. 2013

OmniAb

OmniChicken

POWERED BY EVOLUTION



GREATER EVOLUTIONARY DISTANCE YIELDS GREATER IMMUNOGENICITY AND MORE ANTIBODY DIVERSITY

OmniTaur: Ultralong CDRH3s Create Novel Binding Domains

UNIQUE STRUCTURAL FEATURES OF ULTRALONG H3 ANTIBODIES



- Novel structure may enable targeting epitopes unreachable by standard antibodies
- Long H3 domains can be expressed on human VH framework, or alone as ~5kD Picobodies™



Stanfield, et.al. Sci Adv (2020) 6(20): eaba0468.

Common Light Chain Platforms for Bispecific Antibodies

STANDARD IgG FORMAT TO DE-RISK DOWNSTREAM DEVELOPMENT†

Bispecifics are a growing area of therapeutics (20% of mAbs in clinic)

~30% of new OmniAb programs seek to use OmniFlic or OmniClic

OmniFlic®



Rearranged human VK3-15 light chain combined with diversifying heavy chain

OmniClic®



"Germlining" human VK3-15 light chain combined with diversifying heavy chain



Simple reformatting from monospecific into bispecific for efficient production



Bispecific IgG



Monospecific IgG

Common light chain for OmniFlic and OmniClic allows interchangeability between the platforms

†The Evolution of Bispecifc Antibodies, Nimish Gera
https://doi.org/10.1080/14712598.2022.2040987

OmniAb®

Antibody Repertoires

NUMEROUS OPTIONS AVAILABLE TO ADDRESS DIVERSE PARTNER OBJECTIVES

Host	V genes	Structural and immunological features	Benefits for therapeutics discovery and development
OmniMouse	• Full human V gene diversity • Choice of light chain isotype	• Diverse V gene usage and mixed genetic backgrounds	• Widely accessible and flexible workflows
OmniRat	• Full human V gene diversity • Choice of light chain isotype	• Diverse V gene usage and mixed genetic backgrounds • Distinctive target recognition	• Industry standard • Widely accessible and flexible workflows • Extensive track record
OmniChicken	• Single framework • VH3/VK3 or VH3/VL1	• Evolutionarily divergent host system for robust immune responses	• Diverse and new epitope coverage • High homology targets • Excellent physical properties
OmniFlic	• Full human VH gene diversity with non-diversifying VK3	• Fixed light chain for bispecific applications	• Bispecific applications leveraging standard IgG format
OmniClic	• Single framework • VH3/non-diversifying VK3	• Fixed light chain for bispecific applications	• Diverse epitope coverage • Excellent physical properties • Ease of manufacturing
OmniTaur	• Single framework • VH4/VL1	• Ultralong CDR-H3's for enormous structural diversity	• Access cryptic epitopes • Unique modalities (*Picobodies*™) • Building blocks for multispecific molecules

Screening Platforms

Create Diverse Antibody Pools | Screen Antibody Candidates | Identify the Right Antibody



Our powerful single B-cell screening technologies, ***xPloration®*** **and GEM assay**, **bypass bottlenecks of hybridoma workflows**

AI-driven multi-parameter screening of **tens of millions** of cells in **hours instead of weeks**

Technologies enable **screening against difficult targets**: GPCRs, ion channels and surface antigens

OmniAb

The OmniAb Platform

Our discovery teams are flexibly positioned to work closely with partners to identify the right antibody

- Data from multi-parameter screening and performance assays used in combination with bioinformatics
- NGS hit expansion to identify variant antibodies with improved characteristics
- High-throughput epitope binning and kinetics analysis, and target-specific functional assays
- Proprietary assays for ion channel and transporter targets



Ion Channels and Transporters

WE HAVE EXTENSIVE BIOLOGICAL CAPABILITIES FOR ION CHANNELS AND TRANSPORTERS

Proprietary cell lines enable high-speed antigen production

Proprietary assays leveraged for discovery and characterization of antibodies



Cutting-edge assays facilitate high-throughput screens in our GEM and *xPloration*® platforms

Within OmniAb, Inc. are differentiated capabilities for viable *target-to-lead* delivery for difficult and high-value ion channel and transporter targets

OmniAb®

Leveraging *Biological Intelligence*™ with Computational Tools

Biological Intelligence

OmniRat
OmniChicken
OmniMouse
OmniTaur
OmniFlic
OmniClic

Differentiated sources of antibody sequences

Model-aided optimization



- Antibody homology modeling
- Computational antibody optimization

***In silico* developability**



- Sequence liability assessment
- Comparison to clinical antibodies
- Structure-based calculations

Sequence databases and bioinformatics



- Customized cloud-based antibody sequence databases
- Large-scale repertoire analysis

OmniAb

OmniAb's History

BEST-IN-CLASS PLATFORM BUILT FROM ~15 YEARS OF INVESTMENT AND STRATEGIC ACQUISITIONS



- *Next-generation animals (Bispecifics, Heavy-Chain, etc.)*
- *Expanded state-of-the-art labs and facilities and added capacity*
- *AI-powered single-cell microcapillary platform expansion*

Strategically built tech platform to optimally harness the power of *Biological Intelligence*™

OmniAb

Growth of Partner Programs

PROGRESSION AND PERFORMANCE IN PROGRAMS BY STAGE OF DEVELOPMENT

21 as of 2016(1)



282 as of 09/30/22(2)



Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and future approvals

(1) Estimated at the time of acquisition of OMT
(2) In August 2022, our partner Jansen received marketing approval in the EU for teclistamab; and in October of 2022, Janssen received accelerated approval for teclistamab by the US FDA

OmniAb

Antibody Repertoire Source Used

ACTIVE PARTNER PROGRAMS

SOURCE USAGE



DISTRIBUTION OF ANTIBODY REPERTOIRE SOURCES USED TOGETHER FOR BISPECIFICS



Multi-species platform provides partners even more diverse repertoires and new target access

Common light chain techs being used for flexibility and bispecific program optionality

OmniAb

Diverse Drug Formats and Modalities

PRECLINICAL AND CLINICAL OMNIAB MOLECULES

FORMATS



MODALITIES



Variety in the formats and modalities used by partners is demonstrating the flexibility of our platform

OmniAb

Select OmniAb Partners

>65 COMPANIES CURRENTLY HAVE ACCESS TO OMNIAB ANTIBODIES

AMGEN

Aptevo™ Therapeutics

Boehringer Ingelheim

基石药业 CSTONE PHARMACEUTICALS

Genmab

GigaGen A Grifols Company

gloria 誉衡生物 BIOSCIENCES

janssen

MERCK

ONO PHARMACEUTICAL CO.,LTD.

Pfizer

sanofi

Seagen®

symphogen a Servier Company

Takeda

WuXi Biologics Global Solution Provider

Key Performance Indicators

TECHNOLOGY AND BUSINESS MODEL ARE HIGHLY SCALABLE

- Strong annual growth in key performance indicators continues
  - **Active Partners:**(1) >30% CAGR 2014 through 2021
  - **Active Programs:**(2) >25% CAGR 2016 through 2021
- Year-to-date numbers (as of 9/30/22) position our business for strong annual growth

Number of Active Partners



Number of Active Programs



Number of Active Clinical Programs and Approved Products



(1) Represents the unique number of partners with whom we have active license agreements or who have an active program.
(2) Represents programs for which an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized.
* Active Programs not tracked prior to acquisition of Open Monoclonal Technology, Inc. in January 2016.

OmniAb

Intellectual Property Advantage

PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CAN CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL

Over 300 patents issued worldwide

- We maintain a broad intellectual property estate with multiple long duration patent families covering each major element of our technology platform
- Licenses are structured so that royalties are linked to the patents for the antibodies discovered with OmniAb, thereby creating a lengthy coverage tail

Antibody Patent Applications Filed by Partners



>65 patent filings by our partners claiming an OmniAb-derived antibody as primary invention, with expiries up to 2041

Patents include: WO2015167293A1, WO2017020291A1, WO2017024515A1, WO2017024146A1, WO2017031104A1, WO2017053748A2, WO2017059196A2, WO2017059243A2, WO2017079121A2, WO2017178493A1, WO2017192567A1, WO2017223111A1, WO2018054241A1, US20180105600A1, WO2018057802 A1, WO2018069500A2, WO2018091661A1, WO2018095932A1, WO2018119016A1, WO2018119246A1, WO2018162749A1, WO2019094265A1, WO2019158645A1, WO2019164891A1, WO2019165982A1, WO2019179391A1, WO2019179422A1, WO2019196868A1, WO2019202041A1, WO2019214624A1, WO2019220368A1, WO2019224711A2, WO2019224713A2, WO2019224717A2, WO2020028479A1, WO2020093023A1, WO2020093024A2, WO2020097099A1, WO2020119719A1, WO2021194481A1, WO2020206251A1, WO2020202097A1, US10968280B2, WO2021019386A1 ,WO2021030488A1, WO2021044005A1, WO2021059075A1, WO2021078219A1, WO2021092196A9, WO2021089704A1, WO2021093764A1, WO2021093849A1, WO2021101975A1, WO2021102173A1, WO2021140222A1, WO2021154761A1, WO2021156326A1, WO2021171257A1, WO2021181366A1, WO2021185934A1, WO2021205361A1, WO2021209495A1, US20210363273A1, WO2022024024A2, WO2022048883A1, WO2022037662A1, WO2022121966A1

OmniAb®

Business Model

OUR AGREEMENTS ARE STRUCTURED TO ALIGN ECONOMIC AND SCIENTIFIC INTERESTS WITH OUR PARTNERS

License partnerships designed to include:

- *Upfront and collaboration/access fees*
- *Milestones*
- *Royalties on commercial sales*

Illustrative Revenue Profiles for Successful Partnered Programs

WEIGHTED TOWARDS DOWNSTREAM SUCCESS

Flexible transaction structures enable optionality for partners while maintaining value for OmniAb



Per-product gross revenue potential, if approved and marketed, of up to $1 billion+ to OmniAb, Inc.

Illustrative Antibody Deal Structure

Profile A



Collaboration/ Access Fees: ~$1M - $2M

Clinical & Regulatory Milestones: ~$10M - $20M

Royalties: ~Low Single Digits

Profile B



Collaboration/ Access Fees: ~$100k - $500k

Clinical & Regulatory Milestones: ~$5M - $15M

Royalties: ~Mid Single Digits

Notes: Deal Economics have evolved over time. Unique deal structures may also be used (e.g., equity stakes, risk-sharing, buy-in options, etc.).
Not representative of Icagen ion channel technology deal structures.

OmniAb

Published Probability of Success and Timelines for Antibodies

	Probability of Success [1]	Cumulative from Program Start	Cumulative from Clinical Start	Time Range in Stage
Discovery	100.0%	100.0%		~4 Years
Preclinical	51.0%	51.0%		
Phase 1	69.0%	35.2%	100.0%	
Phase 2	54.7%	19.2%	54.7%	~5 - 8 Years
Phase 3	34.1%	6.6%	18.7%	
NDA	68.1%	4.5%	12.7%	~1 Year
Marketed	95.4%	4.3%	12.1%	

[1] Source: 2011-2020 Clinical Success Rates, BIO|QLS Advisors|Informa Feb 2021 Report

Building Blocks of Value

New Program Starts *(68 in 2021 and growing)* x Probability of Success x Standard Deal Terms

Research-Stage Programs x Probability of Success x Standard Deal Terms

Existing Approved Products/Clinical-Stage Partnered Pipeline

Collaboration Revenue

Novel Platform Technologies

Proforma Revenue & OpEx

('000s)	2020	2021
License and Milestone Revenue	$ 11,385	$ 14,664
Collaboration Revenue	11,883	20,084
Total Revenues	23,268	34,748
Operating costs and expenses:		
Research and Development	24,796	39,232
Selling, General and Administrative	10,225	16,947
Amortization of Intangibles	11,800	12,968
Other Operating Income	2,070	1,210
Total Operating Costs and Expenses	48,891	70,357*
Income from Operations	$ (25,623)	$ (35,609)

* Includes $31M in non-cash expenses ($16M Dep/Amort and $15M Stock Comp)

OmniAb

Cash Position Provides Long Operational Runway

($ millions)	
Gross Cash Proceeds	$130
Underwriting/Transaction/Other Fees	~$35
Net Cash	~$95
Shares Outstanding	114.8 million

Shares Outstanding includes earnout shares, but excludes OmniAb options, RSUs, PSUs and APAC warrants

BUSINESS IS CLOSE TO BREAK-EVEN CASH FLOW

RECENT TRANSACTION PROVIDES SUFFICIENT CAPITAL TO FUND OPERATIONS FOR FORESEEABLE FUTURE

OmniAb

Share Information (at time of Split)

Common Shares Outstanding	
Ligand Shareholders	82.6
SPAC Shareholders	1.3
Avista Shares	14.6
Basic Share Count	**98.5**
Earnout Shares	
Ligand Shareholders	15.0
Avista	1.3
Total Earnout Shares	**16.3**
RSU/Options/Warrants	
Employee RSU/PSU	1.7
Employee Options	12.6
Public Warrants ($11.50 Strike)	7.7
Avista Warrants ($11.50 Strike)	11.3
Total RSU/Options/Warrants	**33.3**

Earnout Share Summary

- Ligand shareholders received 0.75842 earnout shares for every Ligand share owned
  - 50% of the earnout shares vest at $12.50, 50% vest at $15.00
- Stock must trade for 20 out of 30 consecutive trading days at each respective level for vesting to occur
- 5-year life

OmniAb

Management



Matt Foehr
Chief Executive Officer
Board Member Viking Therapeutics
Former Exec at Ligand Pharmaceuticals,
GlaxoSmithKline,
Stiefel Labs, Connetics Corp.



Kurt Gustafson
Chief Financial Officer
Board Member Xencor, Inc
Former CFO/Exec at
Spectrum Pharmaceuticals,
Halozyme Therapeutics, Amgen



Charles Berkman
Chief Legal Officer
Former General Counsel
at Ligand Pharmaceuticals,
Attorney at Baker & McKenzie,
Lyon & Lyon



Bill Harriman, PhD
SVP, Antibody Discovery
Co-Founder/CSO, Crystal Bioscience
Trellis, Roche, Abgenix
UCSF-Immunology, Haas MBA



Christel Iffland, PhD
SVP, Antibody Technologies
Former Associate Director at Merck KGaA /
EMD Serono, Co-inventor of Avelumab
Dana Farber, Albert Einstein College



Marie-Cecile Van De Lavoir, PhD, DVM
SVP, Technical Operations & Genetics
Co-Founder/COO, Crystal Bioscience
Origen Therapeutics, Inventor Germ Cell Technology
Fulbright Scholar, UCSF, Utrecht, Guelph, Cornell



Doug Krafte, PhD
SVP, Ion Channels
Former Exec at Icagen, Pfizer Pain & Sensory
Disorders, Boehringer Ingelheim, Aurora Biosciences
Univ. Rochester, Vanderbilt

OmniAb

Board of Directors



Carolyn Bertozzi, PhD
Professor of Humanities & Sciences
Stanford University
Investigator HHMRI
Nobel Laureate
Former Board Member Eli Lilly,
Advisor to GlaxoSmithKline
Founder of Multiple Companies
Nom/Gov



Sarah Boyce
CEO, Avidity
Former Akcea Therapeutics,
Ionis Pharmaceuticals, Forest Labs
HC&C Chair



Jennifer Cochran, PhD
Professor of Bioengineering
Stanford University
Founder of multiple companies,
including xCella Biosciences
Nom/Gov Chair, AC



Matt Foehr
CEO, OmniAb, Inc.
Board Member Viking Therapeutics
Former Exec at Ligand Pharmaceuticals,
GlaxoSmithKline, Stiefel Labs,
Connetics Corp.



John Higgins
OmniAb, Inc. Board Chair
CEO and Board Member, Ligand Pharmaceuticals
Former CFO, Connetics Corp.
Board Member Bio-Techne
HC&C



Sunil Patel
Public & Private Biotech Executive
Former Abgenix, Gilead, BiPar and
OncoMed
AC Chair, HC&C



Josh Tamaroff
Partner, Avista Capital Partners
Barclays Capital
Lehman Brothers
AC, Nom/Gov

Committee Assignments

OmniAb

Our Key Areas of Focus Going Forward

WE BELIEVE WE ARE WELL-POSITIONED FOR FUTURE GROWTH WHILE WE MAKE AN ENDURING AND SIGNIFICANT IMPACT ON THE INDUSTRY AND GLOBAL HUMAN HEALTH

WE LEVERAGE A HIGHLY SCALABLE BUSINESS WHERE INVESTMENTS IN TECHNOLOGIES AND INNOVATION ARE INFORMED BY DISCOVERY RELATIONSHIPS WITH OUR PARTNERS

- Partnered Pipeline Development, Expansion and Advancement
- Continued Workflow Versatility Initiatives
- Expanding the Reach of our Platform
- New Technology Development
  Incl. new animal and computational innovations

A FOCUS ON KEY STAKEHOLDERS IS AT OUR FOUNDATION

Team:
Strong culture; hire, develop, motivate the best

Partners:
Focus on customer service and future needs

Investors:
Superior business execution to create value

Community:
Lead with integrity and responsibility

OmniAb

OmniAb, Inc. Summary

- Demand for antibody-based approaches drives the industry's need for cutting-edge discovery technologies
- We maintain a highly scalable business where investments in and extensions of our differentiated technology are informed by a deep portfolio of partnerships
- Our partner pipeline is progressing and expanding
- Recent transaction creates robust financial position that fully funds operations, creates an opportunity to unlock value, and positions the business for future growth



For more information, please visit www.omniab.com

Approved and Clinical-Stage Partner Pipeline

NOW WITH THREE APPROVED PRODUCTS AND 22 ACTIVE CLINICAL-STAGE ANTIBODIES

Partner	Program	Source Animal	Therapy Area	Target	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Approved
gloria誉衡生物 ARCUS BIOSCIENCES	Zimberelimab	OmniRat	Oncology	PD-1						
基石药业 CSTONE PHARMACEUTICALS	Sugemalimab	OmniRat	Oncology	PD-L1						
janssen	Teclistamab	OmniRat	Oncology	BCMA x CD3						
Genentech* A Member of the Roche Group	Tiragolumab	OmniRat	Oncology	TIGIT						
HANALL BIOPHARMA HARBOUR BIOMED IMMUNOVANT	Batoclimab	OmniRat	Immunology	FcRn						
Genmab	GEN1046	OmniRat	Oncology	PD-L1 x 4-1BB						
MERCK	M6223	OmniRat	Oncology	TIGIT						
Aptevo THERAPEUTICS	APVO436	OmniMouse	Oncology	CD123 x CD3						
janssen	JNJ-67371244	OmniMouse	Oncology	CD33 x CD3						
janssen	JNJ-70218902	OmniRat	Oncology	Undisclosed						
janssen	JNJ-78306358	OmniRat	Oncology	HLA-G x CD3						
Genmab	GEN1047	OmniRat	Oncology	B7H4 x CD3						
symphogen a Servier Company	S095017	OmniRat	Oncology	LAG-3						
symphogen a Servier Company	S095018	OmniRat	Oncology	TIM-3						
symphogen a Servier Company	S095024	OmniRat	Oncology	CD73						
symphogen a Servier Company	S095029	OmniRat	Oncology	NKG2A						
abbvie †	TNB-383B	OmniFlic	Oncology	BCMA x CD3						
AstraZeneca †	TNB-486	OmniFlic	Oncology	CD19 x CD3						
AMGEN †	AMG 340	OmniFlic	Oncology	PSMA x CD3						
SalubrisBio	SAL003	OmniRat	Metabolic	PCSK9						
CURON	CN1	OmniRat	Oncology	Undisclosed						
Zhilkang Hongyi	Undisclosed	OmniRat	Oncology	Undisclosed						
Boehringer Ingelheim	Undisclosed	OmniChicken	Undisclosed	Undisclosed						
Undisclosed	Undisclosed	OmniRat	Gastrointestinal	Undisclosed						
MERCK	M9140	OmniRat	Oncology	CEACAM-5						

Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020
Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved in China.
* Indicates programs with fully paid licenses.
† Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics.

Confidential

Recent News Flow from Partners

SELECT RECENT DEVELOPMENTS SHOW CONTINUED MOMENTUM AND PLATFORM VALUE

Geography & Indication Expansion

Sugemalimab
(PD-L1)

- Approved in China (CStone/ Pfizer), EQRx now targeting first regulatory filings ex-US before year-end
- Cstone/Pfizer announced China approval in added indication (stage III non-small cell lung cancer)

Recently Approved

Teclistamab
(BCMA x CD3)

- Clinical data published in *New England Journal of Medicine*
- EU approval received in late August; $10M milestone to OmniAb on first sale in EU
- FDA approval received in late October; $25M milestone to OmniAb upon first sale in the U.S.

Additional Late-Phase Trials

Batoclimab
(FcRn)

- Now pursuing 5 indications, all Phase 2 or Pivotal/Phase 3:
  - Myasthenia Gravis
  - Thyroid Eye Disease
  - Chronic Inflammatory Demyelinating Polyneuropathy
  - Graves' Disease
  - Warm Autoimmune Hemolytic Anemia

Entering Phase 2

M6223
(TIGIT)

- Phase 2 trial started recently for Avelumab plus other agents, including M6223, in urothelial carcinoma

Phase 2 Progression

GEN1046
(PD-L1 x 4-1BB)

- Announced data from clinical expansion cohorts and progression

OmniAb

Zimberelimab

THE FIRST APPROVED OMNIRAT-DERIVED ANTIBODY

- In August of 2021, zimberelimab (GLS-010), an OmniAb-derived fully human anti-PD-1 mAb, was approved in China for the treatment of recurrent or refractory classical Hodgkin's lymphoma
  - Marked the first approval of an OmniAb-derived mAb
- In 2015, GloriaBio contracted with WuXi Biologics to discover and develop zimberelimab in China, using OmniRat
  - Zimberelimab entered clinic in March 2017, and NDA was submitted to China NMPA in February 2020
  - GloriaBio is also conducting trials in advanced solid tumors, and was granted Breakthrough Therapy designation for the treatment of patients with recurrent/metastatic cervical cancer
- Zimberelimab is being developed by Arcus Biosciences (in collaboration with Gilead) in North America, Europe, Japan and certain other territories through a 2017 agreement
  - Arcus is conducting Phase 2 and 3 clinical trials investigating zimberelimab as part of combination therapy in lung, prostate, colorectal, pancreatic and GI cancers

Sugemalimab

THE SECOND APPROVED OMNIRAT-DERIVED ANTIBODY

- Fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) mAb, which may reduce risk of immunogenicity and toxicity, a unique advantage over similar drugs
- Sugemalimab (Cejemly®) was approved in China in June of 2022 for unresectable stage III non-small cell lung cancer (NSCLC) following concurrent or sequential chemoradiotherapy
  - Previously approved in China in December 2021, and launched in January 2022, for first-line treatment of metastatic non-squamous NSCLC in combination with chemotherapy
  - Becomes first anti-PD-1/PD-L1 mAb approved for stage III NSCLC, and is also the only one approved for both stage III and stage IV NSCLC
- Pfizer responsible for commercializing in China via 2020 strategic collaboration with CStone
- EQRx licensed exclusive rights to sugemalimab for development / commercialization outside of China, targeting first regulatory filings ex-US in 2H 2022

Teclistamab

APPROVED BISPECIFIC ANTIBODY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

- A fully humanized IgG4, T-cell redirecting, bispecific antibody targeting both BCMA (B-cell maturation antigen) and CD3
  - Discovered in part with the OmniAb platform technology (anti-BMCA portion)
- In December 2021 and January 2022, Janssen submitted a BLA to the FDA and a MAA to the EMA, respectively, for approval in the treatment of relapsed or refractory multiple myeloma
  - Granted Orphan Drug Designation and Breakthrough Therapy Designation by FDA, and Orphan Drug Designation and a PRIority MEdicines (PRIME) designation by EMA
- At ASCO 2022, Janssen presented updated efficacy and safety results from Phase 1/2 MajesTEC-1 study, demonstrating continued deep and durable responses in the treatment of RRMM; results from MajesTEC-1 were also published in *The New England Journal of Medicine*
- Janssen received conditional marketing authorization (CMA) by the European Commission in August of 2022 and accelerated approval by the US FDA in October of 2022
  - Under the terms of the licensing agreement with an affiliate of Janssen, OmniAb, Inc. is eligible to receive a $25 million milestone payment upon first commercial sale in US and a $10 million milestone payment upon first commercial sale in Europe(1)

(1) United Kingdom, Italy, Germany, France or Spain